Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCEL Atreca	$0.09	$0.09	$0.05 ▼ $1.20	$3.57M	1.03	4.61 million shs	N/A
KURA Kura Oncology	$6.35 +1.1%	$6.07	$5.41 ▼ $23.48	$549.72M	0.4	1.27 million shs	1.20 million shs
MGNX MacroGenics	$1.58 -1.9%	$1.48	$0.99 ▼ $5.77	$99.68M	1.59	847,064 shs	343,377 shs
MGTA Magenta Therapeutics	$0.70 -7.7%	$0.53	$0.32 ▼ $2.07	$42.44M	2.12	848,835 shs	376,000 shs
MIST Milestone Pharmaceuticals	$1.38 -11.5%	$1.65	$0.63 ▼ $2.75	$73.78M	0.96	1.09 million shs	6.99 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCEL Atreca	0.00%	0.00%	0.00%	0.00%	0.00%
KURA Kura Oncology	+1.11%	+11.80%	-1.40%	+5.31%	-71.64%
MGNX MacroGenics	-1.86%	+16.18%	+3.95%	+25.40%	-66.38%
MGTA Magenta Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
MIST Milestone Pharmaceuticals	-11.54%	-36.41%	-16.36%	+65.39%	-11.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCEL Atreca	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	4.519 of 5 stars	4.4	2.0	0.0	4.7	2.9	0.8	0.6
MGNX MacroGenics	4.3424 of 5 stars	3.2	4.0	0.0	4.4	2.0	2.5	0.6
MGTA Magenta Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	2.7634 of 5 stars	3.2	4.0	0.0	0.0	3.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCEL Atreca	0.00	N/A	N/A	N/A
KURA Kura Oncology	2.86	Moderate Buy	$24.50	285.83% Upside
MGNX MacroGenics	2.40	Hold	$5.71	261.66% Upside
MGTA Magenta Therapeutics	0.00	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	2.40	Hold	$7.00	407.25% Upside

Current Analyst Ratings Breakdown

Latest MGNX, KURA, MIST, MGTA, and BCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/5/2025	MIST Milestone Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$5.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/19/2025	KURA Kura Oncology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00
5/2/2025	KURA Kura Oncology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $11.00
4/29/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00 ➝ $28.00
4/28/2025	KURA Kura Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCEL Atreca	N/A	N/A	N/A	N/A	$2.01 per share	N/A
KURA Kura Oncology	$53.88M	10.20	N/A	N/A	$5.32 per share	1.19
MGNX MacroGenics	$152.43M	0.65	N/A	N/A	$1.85 per share	0.85
MGTA Magenta Therapeutics	N/A	N/A	N/A	N/A	$1.23 per share	N/A
MIST Milestone Pharmaceuticals	$1M	73.77	N/A	N/A	$0.25 per share	5.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCEL Atreca	-$97.16M	-$2.50	N/A	N/A	N/A	N/A	-157.90%	-71.39%	N/A
KURA Kura Oncology	-$173.98M	-$2.10	N/A	N/A	N/A	N/A	-43.62%	-29.13%	8/6/2025 (Estimated)
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-36.23%	-59.84%	-23.45%	8/5/2025 (Estimated)
MGTA Magenta Therapeutics	-$76.46M	N/A	0.00	∞	N/A	N/A	-70.88%	-57.27%	N/A
MIST Milestone Pharmaceuticals	-$41.52M	-$0.78	N/A	N/A	N/A	N/A	-329.85%	-67.20%	8/6/2025 (Estimated)

Latest MGNX, KURA, MIST, MGTA, and BCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	MGNX MacroGenics	-$0.59	N/A	N/A	N/A	$28.06 million	N/A
5/14/2025	Q1 2025	MIST Milestone Pharmaceuticals	-$0.19	-$0.31	-$0.12	-$0.31	N/A	N/A
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCEL Atreca	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
MGTA Magenta Therapeutics	N/A	N/A	N/A	N/A	N/A
MIST Milestone Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCEL Atreca	N/A	1.58	1.58
KURA Kura Oncology	0.02	8.07	8.07
MGNX MacroGenics	N/A	3.28	3.11
MGTA Magenta Therapeutics	N/A	19.49	19.49
MIST Milestone Pharmaceuticals	4.06	4.67	4.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCEL Atreca	37.47%
KURA Kura Oncology	N/A
MGNX MacroGenics	96.89%
MGTA Magenta Therapeutics	47.53%
MIST Milestone Pharmaceuticals	86.18%

Insider Ownership

Company	Insider Ownership
BCEL Atreca	11.30%
KURA Kura Oncology	6.40%
MGNX MacroGenics	13.00%
MGTA Magenta Therapeutics	15.18%
MIST Milestone Pharmaceuticals	19.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCEL Atreca	130	39.62 million	35.15 million	Optionable
KURA Kura Oncology	130	86.57 million	81.03 million	Optionable
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable
MGTA Magenta Therapeutics	67	60.67 million	51.46 million	Not Optionable
MIST Milestone Pharmaceuticals	30	53.46 million	43.04 million	Optionable

MGNX, KURA, MIST, MGTA, and BCEL Headlines

Recent News About These Companies

US FDA accepts for review Milestone Pharma’s response to CRL for Cardamyst nasal spray

July 14 at 2:56 AM | pharmabiz.comP

Milestone Pharmaceuticals Inc. (MIST) Stock Price Today - WSJ

July 11, 2025 | wsj.com

Milestone says heart disorder therapy under FDA review again

July 11, 2025 | msn.com

Milestone Pharmaceuticals stock plunges on public offering announcement

July 11, 2025 | au.investing.com

Milestone Pharmaceuticals Shares Drop Sharply After Public Offering Announcement

July 11, 2025 | msn.com

Why Is Milestone Pharmaceuticals Stock Plunging On Friday?

July 11, 2025 | benzinga.com

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

July 11, 2025 | benzinga.com

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

July 11, 2025 | globenewswire.com

Milestone Pharmaceuticals proposes capital raise via securities offering

July 11, 2025 | msn.com

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

July 11, 2025 | finance.yahoo.com

Milestone Pharmaceuticals Announces Proposed Public Offering

July 11, 2025 | globenewswire.com

Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

July 11, 2025 | globenewswire.com

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Analysts

July 11, 2025 | americanbankingnews.com

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of "Hold" from Analysts

July 11, 2025 | marketbeat.com

Milestone Pharmaceuticals Inc. (MIST) - Yahoo Finance

July 9, 2025 | ca.finance.yahoo.com

Milestone Pharmaceuticals (NASDAQ:MIST) Shares Up 11.9% - Here's What Happened

July 8, 2025 | marketbeat.com

Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst

July 7, 2025 | seekingalpha.com

Analysts Conflicted on These Healthcare Names: Milestone Pharmaceuticals (MIST), Exact Sciences (EXAS) and Ascendis Pharma (ASND)

July 2, 2025 | theglobeandmail.com

Milestone Pharmaceuticals Inc (MIST) - Investing.com

June 29, 2025 | investing.com

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

June 16, 2025 | finance.yahoo.com

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

June 16, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX, KURA, MIST, MGTA, and BCEL Company Descriptions

Atreca NASDAQ:BCEL

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Kura Oncology NASDAQ:KURA

$6.35 +0.07 (+1.11%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$6.26 -0.09 (-1.34%)

As of 07/14/2025 07:50 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

MacroGenics NASDAQ:MGNX

$1.58 -0.03 (-1.86%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$1.58 -0.01 (-0.32%)

As of 07/14/2025 05:11 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Magenta Therapeutics NASDAQ:MGTA

Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Milestone Pharmaceuticals NASDAQ:MIST

$1.38 -0.18 (-11.54%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$1.40 +0.02 (+1.45%)

As of 07/14/2025 07:59 PM Eastern

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time